vTv Therapeutics Inc. - (VTVT) News
Filter VTVT News Items
VTVT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest VTVT News From Around the Web
Below are the latest news stories about VTV THERAPEUTICS INC that investors may wish to consider to help them evaluate VTVT as an investment opportunity.
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCERCantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions, announced today that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to Cantex's azeliragon for the treatment of brain metastasis from breast cancer. This new azeliragon designation adds to azeliragon's two other Orphan Drug Designations for the treatment of pancreatic cancer and glioblastoma, re |
vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx ConferenceHIGH POINT, N.C., Dec. 02, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company with a portfolio of novel small molecules and a lead program in diabetes, today announced that management will participate in a fireside chat and be available for one-on-one meetings at the 7th Annual Evercore HealthCONx Conference to be held in Coral Gables. Florida, December 3 – 5, 2024. 7th Annual Evercore HealthCONx Conference Presentation Date:December 4, 2024 |
vTv Therapeutics (NASDAQ:VTVT) adds US$9.5m to market cap in the past 7 days, though investors from five years ago are still down 71%vTv Therapeutics Inc. ( NASDAQ:VTVT ) shareholders should be happy to see the share price up 29% in the last week. But... |
VTv Therapeutics: Q3 Earnings SnapshotHIGH POINT, N.C. (AP) — VTv Therapeutics Inc. VTVT) on Tuesday reported a loss of $4.8 million in its third quarter. On a per-share basis, the High Point, North Carolina-based company said it had a loss of 88 cents. |
vTv Therapeutics Announces 2024 Third Quarter Financial Results and Provides Corporate UpdateHIGH POINT, N.C., Nov. 12, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company with a portfolio of novel small molecules and a lead program in diabetes, today reported financial results for the third quarter ended September 30, 2024, and provided an update on recent corporate developments. "Our cadisegliatin program continues to show promise as a new oral adjunct therapy being investigated for improvement in glycemic control and reduction of |
vTv Therapeutics Faces License Agreement TerminationvTv Therapeutics ( (VTVT) ) has issued an update. OnKure Therapeutics plans to terminate its License Agreement with vTv Therapeutics LLC, ending the development of the ppar-δ agonist program. This move, effective January 2025, might impact investors interested in the pharmaceutical collaborations and the future of vTv’s intellectual property ventures. Learn more about VTVT stock on TipRanks’ Stock Analysis page. |
We're Keeping An Eye On vTv Therapeutics' (NASDAQ:VTVT) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, although... |
VTv Therapeutics: Q2 Earnings SnapshotHIGH POINT, N.C. (AP) — VTv Therapeutics Inc. VTVT) on Thursday reported a loss of $5.2 million in its second quarter. On a per-share basis, the High Point, North Carolina-based company said it had a loss of 81 cents. |
vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate UpdateScreened first patient in cadisegliatin pivotal trial for type 1 diabetes (T1D); working to resolve clinical hold Expanded Newsoara Biopharma license agreement for PDE4 inhibitor HPP737 to a global license effective upon payment of the $20 million upfront fee HIGH POINT, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today reported financial |
FDA Puts Brake On vTv Therapeutics' Diabetes Candidate Program, Including Late-Stage Study, Stock TanksvTv Therapeutics Inc. (NASDAQ:VTVT) stock is trading lower on Monday. The FDA has placed a clinical hold on the cadisegliatin clinical program, which includes the ongoing CATT1 Phase 3 trial in type 1 diabetes. Cadisegliatin is an oral, liver-selective, glucokinase activator. The company says the drug candidate has been well-tolerated in over 500 subjects to date with up to six months of treatment. Related: Why Is Diabetes Focused vTv Therapeutics Stock Trading Higher Today? Selectively acting o |